Physicians' Academy for Cardiovascular Education

Uninterrupted NOAC superior to warfarin for ablation of AF in the RE-CIRCUIT study

Safety and Efficacy of Uninterrupted Anticoagulation With Dabigatran Etexilate Versus Warfarin in Patients Undergoing Catheter Ablation of Atrial Fibrillation: The RE-CIRCUIT Study

Presented at ACC.17 by Hough Calkins

News - Mar. 19, 2017

Main results


In AF patients undergoing ablation, periprocedural anticoagulation with uninterrupted dabigatran (150 mg twice daily) was associated with fewer bleeding complications compared with uninterrupted warfarin. The results of this study suggest that uninterrupted dabigatran administration is a better anticoagulation strategy for AF ablation as compared with warfarin. The availability of the specific reversal agent idarucizumab, while not needed in any patient in this trial, further motivates the adoption of uninterrupted dabigatran as the preferred anticoagulation strategy in patients undergoing AF ablation.

The commentator noted during the press conference that this study will most likely affect clinical practice, as it refutes some of the bleeding concerns. Now, a periprocedural strategy is available that is associated with minimal bleeding and reversal at hand.


Our coverage of ACC.17 is based on the information provided during the congress.

This study was published today in NEJM

Share this page with your colleagues and friends: